Philips, a global leader in health technology and IVUS solutions, announced that a worldwide committee of 40 cross-specialty medical experts achieved the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease (PVD) interventions
News | Intra-Vascular Ultrasound (IVUS)
First-ever Global Consensus for the Appropriate Use of IVUS in Peripheral Vascular Disease Interventions

October 20, 2021 — Philips, a global leader in health technology and intravascular ultrasound (IVUS) solutions ...

Home October 20, 2021
Home
The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI). It was presented at VIVA 2021.
News | Drug-Eluting Balloons
18-Month Below-the-Knee Data With MedAlliance’s SELUTION SLR Presented at VIVA

October 20, 2021 — 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a late-breaking ...

Home October 20, 2021
Home
the Eluvia stent exhibited superiority with a primary patency rate of 85.4% versus 76.3% with BMS (p=0.0077).1 The analysis also confirmed a significantly greater rate of sustained clinical improvement without reintervention
News | Peripheral Artery Disease (PAD)
Boston Scientific Eluvia Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents

October 20, 2021 — Boston Scientific Corporation announced positive data for the Eluvia Drug-Eluting Vascular Stent ...

Home October 20, 2021
Home
The CorWave LVAD uses a pulse pump rather than a rotary pump to move blood, so it more closely simulates the movement of blood in a read heart.
News | Ventricular Assist Devices (VAD)
Innovative New Pulsatile LVAD Wins 2021 HealthTech Award

October 20, 2021 – CorWave, a French medtech company developing a next-generation heart pump, won the 2021 HealthTech ...

Home October 20, 2021
Home
A radiotherapy treatment plan to ablate a heart to treat ventricular tachycardia (TV) in the ENCORE-VT trial.
Blog
Radiation Therapy to Treat Heart Arrhythmias is a Technology to Watch

Radiation is usually something discussed in cardiology in regards to how it needs to be reduced in the cath lab and in ...

Home October 19, 2021
Home
The Biotricity Biocare Cardiac app for the Samsung Galaxy Watch4 offers mobile cardiac telemetry with real-time monitoring and transmission of ECG information. It also can interface with FDA-cleared devices, including a digital thermometer, a pulse oximeter and a blood pressure cuff.
News | Wearables
Biotricity Launches Biocare Cardiac Application for Samsung's Galaxy Watch4 Series

October 15, 2021 — Biotricity Inc. announced the release of Biocare Cardiac, a personal, cardiac health application for ...

Home October 15, 2021
Home
Videos | Structural Heart
VIDEO: Abbott Structural Heart CMO Shares Views on Future of Valve Interventions

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, was a cardiac surgeon specializing in ...

Home October 15, 2021
Home
7 areas to consider to improve STEMI heart attack care
News | Cardiovascular Business
American Heart Association Offers Approaches to Improve STEMI Heart Attack Care 

October 15, 2021 — The American Heart Association (AHA) released a new policy statement that offers policy ...

Home October 15, 2021
Home
he correlation between poor oral health and COVID-19 severity, as well as the correlation between oral health and delayed recovery, demonstrates a potential need to consider oral health an additional risk factor for cardiac patients who may contract COVID-19. The new sub-study, examining Egyptian cardiac patients, bring presented at ACC Middle East 2021. #COVID19 #SARSCOV2
News | Coronavirus (COVID-19)
Poor Oral Health Impacts COVID severity, Especially in Cardiac Patients

October 15, 2021 — The correlation between poor oral health and COVID-19 (SARS-CoV-2) severity, as well as the ...

Home October 15, 2021
Home
The InspireMD CGuard Embolic Prevention Stent System (EPS) device for the treatment of carotid artery disease (CAD) and stroke prevention has received reimbursement in France from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS).
News | Stents Carotid
CGuard Embolic Prevention Carotid Stent Receives French Reimbursement Approval 

October 15, 2021 — The InspireMD CGuard Embolic Prevention Stent System (EPS) device for the treatment of carotid artery ...

Home October 15, 2021
Home
Videos | EP Mapping and Imaging Systems
VIDEO: Example of Irregular AFib on EP Electromapping on an Acutus System

An example of the Acutus Medical AcQMap High Resolution Imaging and Mapping System to guide electrophysiology (EP) ...

Home October 14, 2021
Home
Cardiac CTA derived left atrium emptying fraction (LAEF) improves predictive performance of established clinical risk scores and may be used to assess TAVR patient risk during pre-procedure workup and post-procedural surveillance. These images show LAVmax (A and B), LAVmin (C and D), and LAEF using cardiac CTA. LAEF was calculated as (LAVmax-LAVmin)/LAVmax x 100. Given LAVmax of 109 mL and LAVmin of 80 mL, the LAEF was calculated to be 27%. Image courtesy of AJR.
News | Computed Tomography (CT)
Cardiac CTA Parameters Predict Post-TAVR Mortality

October 14, 2021 — Cardiac computed tomography angiography (CTA) derived left atrium emptying fraction (LAEF) improves ...

Home October 14, 2021
Home
Videos | Structural Heart
VIDEO: How to Perform a Transcaval TAVR Procedure

Tiberio Frisoli, M.D., interventional structural cardiologist, senior staff physician, Henry Ford Hospital, explains how ...

Home October 14, 2021
Home
Draft Recommendations Suggest Not Using Aspirin for Prevention in Many Patients. Risks vs. benefits of aspirin shows risks outweigh benefits in preventing heart attacks and strokes in many patients.
Feature | Pharmaceuticals | By Dave Fornell, DAIC Editor
Draft Recommendations Suggest Not Using Aspirin for Prevention in Many Patients

There has been debate in recent years over balancing the risks vs. benefits of aspirin for the prevention of heart ...

Home October 13, 2021
Home
FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction. he U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for empagliflozin (Jardiance) as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF).
News | Pharmaceuticals
FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction

October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for ...

Home October 07, 2021
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now